Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Average Rating of “Hold” from Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been given a consensus rating of “Hold” by the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $76.50.

A number of equities research analysts recently weighed in on PBH shares. Jefferies Financial Group lowered their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the sale, the vice president owned 41,048 shares of the company’s stock, valued at approximately $2,706,294.64. This trade represents a 2.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.40% of the company’s stock.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Large investors have recently added to or reduced their stakes in the stock. Nordea Investment Management AB grew its position in shares of Prestige Consumer Healthcare by 547.4% during the fourth quarter. Nordea Investment Management AB now owns 615,215 shares of the company’s stock worth $37,811,000 after acquiring an additional 520,186 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in Prestige Consumer Healthcare by 4.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock valued at $100,893,000 after purchasing an additional 70,376 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in Prestige Consumer Healthcare in the 3rd quarter valued at about $1,890,000. Tributary Capital Management LLC boosted its stake in Prestige Consumer Healthcare by 157.3% during the 3rd quarter. Tributary Capital Management LLC now owns 379,410 shares of the company’s stock valued at $23,675,000 after purchasing an additional 231,969 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in Prestige Consumer Healthcare by 30.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 459,228 shares of the company’s stock valued at $28,656,000 after purchasing an additional 106,224 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $52.47 on Friday. The stock has a market capitalization of $2.48 billion, a PE ratio of 13.88, a price-to-earnings-growth ratio of 1.72 and a beta of 0.47. The business’s fifty day moving average price is $64.69 and its 200 day moving average price is $62.92. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93. Prestige Consumer Healthcare has a 12-month low of $51.28 and a 12-month high of $89.37.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The business had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. During the same period last year, the company posted $1.22 earnings per share. The firm’s revenue for the quarter was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Equities research analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).